Literature DB >> 9741505

Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.

C F Lundergan1, J S Reiner, W F McCarthy, K S Coyne, R M Califf, A M Ross.   

Abstract

OBJECTIVES: The purpose of this study was to determine patient characteristics that are a priori predictors of early infarct related artery patency following thrombolytic therapy, and to provide a paradigm which may identify patients who would be most likely to achieve restoration of normal (TIMI 3) coronary flow in response to thrombolytic therapy.
BACKGROUND: Restoration of infarct-related artery perfusion in acute myocardial infarction is necessary for preservation of ventricular function and mortality reduction. Clinical variables that are a priori predictors of early patency with currently available thrombolytic regimens have not been fully characterized.
METHODS: The probability of early infarct-related artery patency (TIMI 3 flow) was determined by multivariable logistic regression. We determined a reduced (parsimonious) model for predicting early (90 min) infarct-related artery patency (TIMI grade 3) based on data from 1,030 patients in the GUSTO-I Angiographic study.
RESULTS: Predictors of 90 min TIMI 3 flow are use of an accelerated t-PA regimen (vs. streptokinase containing regimens) (chi2=39.1; p < or = 0.0001), infarct related artery (RCA/Lcx vs. LAD) (chi2=12.7; p=0.0004), body weight (chi2=10.3; p=0.001) and history of smoking (chi2=7.4; p=0.007). Time from symptom onset to treatment was not significant (p=0.71).
CONCLUSIONS: The efficacy of currently available thrombolytic regimens is chiefly dependent on choice of thrombolytic regimen, body weight, infarct-related coronary artery and smoking history. Clinical variables alone correctly predict a priori TIMI 3 flow in the infarct-related artery 64% of the time. Patients with body weights greater than 85 kg are at a significant disadvantage with regard to achieving successful thrombolysis compared to those with lesser body weights.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741505     DOI: 10.1016/s0735-1097(98)00278-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention.

Authors:  Gjin Ndrepepa; Dritan Keta; Robert A Byrne; Stefanie Schulz; Julinda Mehilli; Melchior Seyfarth; Albert Schömig; Adnan Kastrati
Journal:  Heart Vessels       Date:  2010-01-21       Impact factor: 2.037

Review 2.  Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in India.

Authors:  Santanu Guha; Rishi Sethi; Saumitra Ray; Vinay K Bahl; S Shanmugasundaram; Prafula Kerkar; Sivasubramanian Ramakrishnan; Rakesh Yadav; Gaurav Chaudhary; Aditya Kapoor; Ajay Mahajan; Ajay Kumar Sinha; Ajit Mullasari; Akshyaya Pradhan; Amal Kumar Banerjee; B P Singh; J Balachander; Brian Pinto; C N Manjunath; Chandrashekhar Makhale; Debabrata Roy; Dhiman Kahali; Geevar Zachariah; G S Wander; H C Kalita; H K Chopra; A Jabir; JagMohan Tharakan; Justin Paul; K Venogopal; K B Baksi; Kajal Ganguly; Kewal C Goswami; M Somasundaram; M K Chhetri; M S Hiremath; M S Ravi; Mrinal Kanti Das; N N Khanna; P B Jayagopal; P K Asokan; P K Deb; P P Mohanan; Praveen Chandra; Col R Girish; O Rabindra Nath; Rakesh Gupta; C Raghu; Sameer Dani; Sandeep Bansal; Sanjay Tyagi; Satyanarayan Routray; Satyendra Tewari; Sarat Chandra; Shishu Shankar Mishra; Sibananda Datta; S S Chaterjee; Soumitra Kumar; Soura Mookerjee; Suma M Victor; Sundeep Mishra; Thomas Alexander; Umesh Chandra Samal; Vijay Trehan
Journal:  Indian Heart J       Date:  2017-03-23

Review 3.  Recent advances in the diagnosis and treatment of acute myocardial infarction.

Authors:  Koushik Reddy; Asma Khaliq; Robert J Henning
Journal:  World J Cardiol       Date:  2015-05-26

4.  The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome.

Authors:  Peter C Kievit; Marc A Brouwer; Gerrit Veen; Wim R M Aengevaeren; Freek W A Verheugt
Journal:  J Thromb Thrombolysis       Date:  2008-06-26       Impact factor: 2.300

5.  Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis.

Authors:  Giuseppe Patti; Carolina Fossati; Annunziata Nusca; Simona Mega; Vincenzo Pasceri; Andrea D'Ambrosio; Barbara Giannetti; Ombretta Annibali; Giuseppe Avvisati; Germano Di Sciascio
Journal:  J Thromb Thrombolysis       Date:  2008-06-25       Impact factor: 2.300

6.  Debate: Should the elderly receive thrombolytic therapy or primary angioplasty?

Authors:  Harvey D White
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

7.  Smoker's Paradox in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Tanush Gupta; Dhaval Kolte; Sahil Khera; Prakash Harikrishnan; Marjan Mujib; Wilbert S Aronow; Diwakar Jain; Ali Ahmed; Howard A Cooper; William H Frishman; Deepak L Bhatt; Gregg C Fonarow; Julio A Panza
Journal:  J Am Heart Assoc       Date:  2016-04-22       Impact factor: 5.501

8.  The Effect of Periprocedural Clinical Factors Related to the Course of STEMI in Men and Women Based on the National Registry of Invasive Cardiology Procedures (ORPKI) between 2014 and 2019.

Authors:  Janusz Sielski; Karol Kaziród-Wolski; Karolina Jurys; Paweł Wałek; Zbigniew Siudak
Journal:  J Clin Med       Date:  2021-12-06       Impact factor: 4.241

9.  ​Circulating Cytokines in Myocardial Infarction Are Associated With Coronary Blood Flow.

Authors:  Anna Kalinskaya; Oleg Dukhin; Anna Lebedeva; Elena Maryukhnich; Georgy Rusakovich; Daria Vorobyeva; Alexander Shpektor; Leonid Margolis; Elena Vasilieva
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.